Bispecific T-Cell Engager
Showing 9976 - 10000 of >10,000
Oral Squamous Cell Carcinoma Trial in Louisville, Cincinnati, Houston (PRV111 (Cisplatin Transmucosal System))
Completed
- Oral Squamous Cell Carcinoma
- PRV111 (Cisplatin Transmucosal System)
-
Louisville, Kentucky
- +4 more
Nov 23, 2021
Ensatinib in alK-positive Patients Undergoing Initial Treatment
Recruiting
- ALK Positive
- +2 more
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Nov 16, 2021
Skin Squamous Cell Carcinoma, Appendix Adenocarcinoma, Rare Lesion Trial in Houston (Atezolizumab, Cobimetinib)
Active, not recruiting
- Skin Squamous Cell Carcinoma
- +11 more
-
Houston, TexasM D Anderson Cancer Center
Mar 3, 2022
Neurofilament Light- Chain in Ataxia Telangiectasia
Unknown status
- Ataxia Telangiectasia
- blood withdrawal
-
Frankfurt, Hessen, GermanyUniversity Children´s Hospital, Ped. Pulmonology
Oct 28, 2020
Hepatocellular Cancer Trial in Clichy (IRM with a 5-minute- additional sequence to measure FRM)
Completed
- Hepatocellular Cancer
- IRM with a 5-minute- additional sequence to measure FRM
-
Clichy, FranceValérie Vilgrain
Jun 20, 2022
ADHD Trial in Majadahonda (The Secret Trail of Moon (MOON): Cognitive training with Serious Video Game, Usual treatment for
Recruiting
- Attention Deficit Hyperactivity Disorder
- The Secret Trail of Moon (MOON): Cognitive training with Serious Video Game
- Usual treatment for ADHD
-
Majadahonda, Madrid, SpainPuerta de Hierro University Hospital
Aug 21, 2023
Psoriasis Trial in San Francisco (Skin biopsy, Blood draw)
Completed
- Psoriasis
- Skin biopsy
- Blood draw
-
San Francisco, CaliforniaUCSF Psoriasis Center
Sep 17, 2021
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the
Recruiting
- Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck
- +2 more
- Atezolizumab
- +2 more
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Jan 19, 2022
Esophageal Squamous Cell Carcinoma Trial (chidamide + camrelizumab)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- chidamide + camrelizumab
- (no location specified)
Jul 29, 2021
Advanced Kidney Cancer, Kidney Cancer, Clear Cell Renal Cell Carcinoma Trial in United States (Guadecitabine, Durvalumab)
Active, not recruiting
- Advanced Kidney Cancer
- +2 more
-
Chicago, Illinois
- +4 more
Feb 16, 2022
Apheresis to Obtain Plasma or White Blood Cells for Laboratory
Recruiting
- Healthy Volunteers
- HIV
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 18, 2022
Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor Trial (radiation, biological, procedure)
Withdrawn
- Hematopoietic and Lymphoid Cell Neoplasm
- Malignant Solid Neoplasm
- Copper Cu 64-DOTA-pembrolizumab
- +2 more
- (no location specified)
Jun 7, 2022
CNS Lymphoma, Secondary CNS Lymphoma Trial run by the National Cancer Institute (NCI) (TEDD-R, TEDDI-R, Ibrutinib)
Recruiting
- Central Nervous System Lymphoma
- Secondary Central Nervous System Lymphoma
- TEDD-R
- +5 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
Traumatic Brain Injury Trial (Mesenchymal Stromal Cells (MSC), )
Not yet recruiting
- Traumatic Brain Injury
- Mesenchymal Stromal Cells (MSC)
- placebo
- (no location specified)
Nov 17, 2023
Oral Mucositis, Chemotherapeutic Toxicity, Childhood Cancer Trial in Porto Alegre (Diode Semiconductor, Duo, Gemini laser)
Recruiting
- Oral Mucositis
- +2 more
- Diode Semiconductor, Duo
- Gemini laser
-
Porto Alegre, Rio Grande Do Sul, BrazilFederal University of Rio Grande do Sul
Mar 30, 2023
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Tumor in the Lymph Nodes, Metastatic Prostate Carcinoma Trial in
Recruiting
- Castration-Resistant Prostate Carcinoma
- +3 more
- Avelumab
- +4 more
-
Los Angeles, California
- +22 more
Feb 2, 2023
Covid19, Cytokine Storm, Regulation of Inflammatory Response Trial in Mexico (Collagen-Polyvinylpyrrolidone)
Recruiting
- Covid19
- +3 more
-
Mexico, Cdmx, MexicoInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubi
Feb 13, 2021
HIV, Burkitt's Lymphoma Trial in Italy (Induction Phase, Consolidation Phase (on day +50), Intensification phase)
Completed
- HIV
- Burkitt's Lymphoma
- Induction Phase
- +4 more
-
Aviano (PN), Italy
- +7 more
Aug 2, 2022
Cancer Stem Cell Specific Aptamer's Ability to Detect Blood
Completed
- Pancreatic Neoplasm
-
Seoul, Korea, Republic ofYonsei University Health System, Severance Hospital
Feb 15, 2023
CaboCHECK - Cabozantinib in Adult Advanced Renal Cell Carcinoma
Terminated
- Advanced Renal Cell Carcinoma (All Subtypes)
- Metastatic Renal Cell Carcinoma (All Subtypes)
- Documentation
-
Essen, Nordrhein-Westfalen, Germany
- +1 more
Dec 21, 2022
Tumors Trial in Worldwide (Dostarlimab)
Recruiting
- Neoplasms
- Dostarlimab
-
Birmingham, Alabama
- +105 more
Nov 17, 2022
Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Suzhou (CD19/22 CART, Tislelizumab)
Unknown status
- Relapsed Non Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma
- CD19/22 CART
- Tislelizumab
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Jul 30, 2021
Glioma Trial in Portland (Fludeoxyglucose F-18, Gadoterate Meglumine, Contrast-enhanced Magnetic Resonance Imaging)
Not yet recruiting
- Glioma
- Fludeoxyglucose F-18
- +3 more
-
Portland, OregonOHSU Knight Cancer Institute
Jun 30, 2023
Pneumonia, Appendicitis, Diverticulitis Trial in Pittsburgh (Blue Light)
Recruiting
- Pneumonia
- +2 more
- Blue Light
-
Pittsburgh, PennsylvaniaUPMC-Presbyterian Hospital
Mar 1, 2022